Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CTT Pharmaceutical HoldingsCTTH -0.13% EBIT per Share is $-0.00 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 809 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks better than 96.66% on this metric.
CTT Pharmaceutical Holdings's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 80.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 53.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 51.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for CTT Pharmaceutical Holdings's EBIT per Share or its related term are showing as below:
CTTH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -71 Med: 18.45 Max: 92.6
Current: 80.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of CTT Pharmaceutical Holdings was 92.60% per year. The lowest was -71.00% per year. And the median was 18.45% per year.
CTTH's 3-Year EBIT Growth Rate is ranked better than 96.66% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs CTTH: 80.60
CTT Pharmaceutical Holdings (OTCPK:CTTH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
CTT Pharmaceutical Holdings EBIT per Share Related Terms
CTT Pharmaceutical Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTT Pharmaceutical Holdings (CTTH) has a EBIT per Share of $-0.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CTT Pharmaceutical Holdings and its competitors. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #27 out of 809 companies in the Drug Manufacturers industry, placing it in the top 3.3%.
Is CTT Pharmaceutical Holdings' EBIT per Share too high?
CTT Pharmaceutical Holdings' current EBIT per Share is $-0.00. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #27 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does CTT Pharmaceutical Holdings' EBIT per Share compare to BUDZ and SBFM?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #27 out of 809 companies for EBIT per Share. This places CTT Pharmaceutical Holdings in the top 3% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CTT Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current EBIT per Share is $-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current EBIT per Share of $-0.00. The current EBIT per Share is $-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current EBIT per Share is $-0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTTH has been successfully added to your 
